When is ITRM's latest earnings report released?
The most recent financial report for Iterum therapeutics plc (ITRM) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ITRM's short-term business performance and financial health. For the latest updates on ITRM's earnings releases, visit this page regularly.
What is the operating profit of ITRM?
According to the latest financial report, Iterum therapeutics plc (ITRM) reported an Operating Profit of -7.73M with an Operating Margin of -1,982.31% this period, representing a decline of 58.2% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is ITRM's revenue growth?
In the latest financial report, Iterum therapeutics plc (ITRM) announced revenue of 390K, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does ITRM have?
As of the end of the reporting period, Iterum therapeutics plc (ITRM) had total debt of 33.74M, with a debt ratio of 1.04. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ITRM have?
At the end of the period, Iterum therapeutics plc (ITRM) held Total Cash and Cash Equivalents of 11.03M, accounting for 0.34 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ITRM go with three margins increasing?
In the latest report, Iterum therapeutics plc (ITRM) did not achieve the “three margins increasing” benchmark, with a gross margin of 94.9%%, operating margin of -1,982.31%%, and net margin of -2,302.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ITRM's profit trajectory and future growth potential.
Is ITRM's EPS continuing to grow?
According to the past four quarterly reports, Iterum therapeutics plc (ITRM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ITRM?
Iterum therapeutics plc (ITRM)'s Free Cash Flow (FCF) for the period is -7.46M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 179.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ITRM?
The latest valuation data shows Iterum therapeutics plc (ITRM) has a Price-To-Earnings (PE) ratio of -0.92 and a Price/Earnings-To-Growth (PEG) ratio of -0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
